Developing inhaled therapeutics for serious respiratory diseases.
Kyu Therapeutics is developing innovative inhaled medicines for serious respiratory diseases, including idiopathic pulmonary fibrosis (IPF) and interstitial lung diseases (ILDs), with the aim of delivering therapeutic effects directly to the lung.
About
About Kyu Therapeutics
Representative
Kazuhiro Ito
Representative Director of Kyu Therapeutics Inc.
Kyu Therapeutics is a biotechnology company focused on the development of inhaled therapeutics for serious respiratory diseases.
Our approach is based on targeted local delivery to the lung, aiming to enhance therapeutic exposure at the site of disease while reducing unnecessary systemic burden.
By combining respiratory disease biology, formulation strategy, and translational development expertise, we aim to create differentiated treatment options for patients with high unmet medical needs.
Targeted Local Delivery
Designed to deliver therapeutic exposure directly to the lung.
Respiratory Disease Focus
Focused on serious respiratory diseases including IPF and ILD.
Translational Development
Built on disease biology, formulation, and development expertise.
Pipeline
Pipeline
Our lead program is designed to explore the potential of inhaled local delivery for fibrotic lung diseases.
KYU001-DPI is our lead preclinical program designed for serious fibrotic respiratory diseases, including IPF and ILD. The program is based on an inhaled delivery approach intended to provide direct exposure to the lung.
Contact
Contact
For partnership, investment, and collaboration inquiries, please contact us.
contact@kyutx.com